Alphabet Inc Class CGoogle Cloud selected as primary infrastructure for BenchSci's EMET platform, expanding cloud usage.

BenchSci announced a strategic, multi-year initiative establishing Google Cloud as the primary infrastructure platform for EMET, its agentic research environment for preclinical drug discovery. The combined solution gives pharmaceutical scientists unified access to BenchSci's proprietary biological knowledge graph—858 million nodes, 2.2 billion relationship edges, and legal access to 16 million closed-access scientific papers—alongside Google's frontier life sciences AI models, including AlphaGenome and AlphaFold 3, within a single environment. BenchSci reports that 70% of drugs fail in the clinic due to fragmented data, and scientists spend half their time manually integrating disparate sources. The majority of the top 20 pharmaceutical companies by revenue are existing BenchSci customers, with 80% of users reporting 60% efficiency gains and some teams achieving up to 50x time savings. BenchSci is also working to integrate EMET into the Google Cloud Marketplace for simplified access and billing.
Alphabet Inc Class CGoogle Cloud selected as primary infrastructure for BenchSci's EMET platform, expanding cloud usage.
Partnership with Google Cloud enhances EMET platform with advanced AI models and infrastructure.